Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial

Pasireotide Acromegaly Study Group, S Petersenn, J Schopohl, A Barkan, P Mohideen, A Colao, R Abs, A Buchelt, Y-Y Ho, K Hu, Andrew Farrall, S Melmed, B M K Biller

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds